Skip to content

Estefanía Moreno

2 papers in the library · 226 citations · publishing 2015-2017

Papers

Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors

PLoS Biology July 9, 2015 Xavier Viñals, Estefanía Moreno, Laurence Lanfumey et al. 211 citations

Activation of cannabinoid CB1 receptors (CB1R) by delta9-tetrahydrocannabinol (THC) causes negative effects including memory deficits, limiting therapeutic use. Behavioral studies in mice lacking 5-HT2A receptors (5-HT2AR) showed a dissociation: THC's antinociceptive effects remained, but its amnesic, anxiolytic-like, and social interaction effects depended on 5-HT2AR, while hypolocomotor, hypothermic, anxiogenic, and antinociceptive effects did not. Biochemical studies revealed CB1R and 5-HT2AR form heteromers in brain regions involved in memory, altering cell signaling and G-protein coupling. Synthetic peptides disrupting heteromerization selectively prevented THC-induced memory impairments, identifying CB1R-5-HT2AR heteromers as targets to separate cognitive deficits from beneficial pain relief.

Detoxification from methadone using low, repeated, and increasing doses of ibogaine: A case report

Journal of Psychedelic Studies April 1, 2017 Clare Wilkins, Rafael G. Dos Santos, Jordi Solà et al. 15 citations

A woman on methadone maintenance treatment for 17 years self-treated with several low and cumulative doses of ibogaine over 6 weeks. Each dose attenuated withdrawal symptoms for hours and reduced tolerance to methadone until all withdrawal signs disappeared. No serious adverse effects occurred, and QTc measures never reached clinically significant scores. Twelve months after treatment, she was no longer on methadone maintenance. This first case report suggests that low and cumulative ibogaine doses may reduce withdrawal symptoms in patients on methadone maintenance treatment, though clinical trials are lacking.